REMARKS

Claims 113-127 are currently pending in the application, and claims 117-127 are withdrawn from consideration as being directed to non-elected subject matter. Claims 113-125 are amended herewith solely to correct inadvertent typographical errors in the numbering of sequence identifiers for SEQ ID NOS:4-6, which the record, and in particular the Preliminary Amendment Regarding Sequence Listing submitted to the PTO on July 27, 2004, clearly shows were disclosed as SEQ ID NOS:31-33, respectively, in the application as originally filed, and subsequently renumbered. See, in the Preliminary Amendment Regarding Sequence Listing submitted to the PTO on July 27, 2004, e.g., rewritten paragraph to replace the paragraph beginning at page 19, line 25 of the specification; rewritten paragraph to replace the paragraph beginning at page 21, line 27 of the specification; rewritten paragraph to replace the paragraph beginning at page 23, line 12 of the specification; rewritten paragraph to replace the paragraph beginning at page 23, line 29 of the specification; rewritten paragraph to replace the paragraph beginning at page 24, line 28 of the specification. No new matter is added by the present amendment.

The subject matter of Group I, claims 113-116, has previously been elected for examination, with the further election, as the single disclosed species, of an isoform-specific antibody that recognizes a human adenine nucleotide translocator 3 polypeptide having an amino acid sequence as set forth in SEQ ID NO:6. For reasons given herein, the human adenine nucleotide translocator 3 polypeptide amino acid sequence set forth in SEQ ID NO:6 was, in Applicants' Response submitted to the PTO on October 20, 2006, inadvertently referred to as "SEQ ID NO:33." The designation of SEQ ID NO:33 in the Response of October 20, 2006, was clearly intended to be a designation of SEQ ID NO:6, insofar as Applicants' "Preliminary Amendment Regarding Sequence Listing" submitted to the PTO on July 27, 2004, repeatedly corrects the occurrences in the specification of "SEQ ID NO:33" to read "SEQ ID NO:6", as also noted above. By the present amendment, the recited sequence identifiers in the claims are consistent with the numbering of sequences as previously introduced by amendment to the

Application No. 10/763,398
Reply to Office Communication dated January 17, 2007

specification. The application, including the Sequence Listing, CRF files and claims, fully complies with the requirements of $37 \text{ C.F.R.} \cdot 1.821 - 1.825$.

As noted in Applicants' Response submitted to the PTO on October 20, 2006, the election of species was made with the understanding that upon the allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim, as provided by 37 C.F.R. § 1.141.

Favorable consideration and a Notice of Allowance are earnestly solicited. The Director is authorized to charge any additional fees due by way of this Amendment, or credit any overpayment, to our Deposit Account No. 19-1090.

Respectfully submitted,

SEED Intellectual Property Law Group PLLC

Stephen J. Rosenman, Ph.D. Registration No. 43,058

SJR:rp

Enclosure:

Copy of Notice to Comply 701 Fifth Avenue, Suite 5400 Seattle, Washington 98104 Phone: (206) 622-4900 Fax: (206) 682-6031

903751_1.DOC